These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 11373466)

  • 1. Randomized, placebo-controlled trial of the anti-tumor necrosis factor antibody fragment afelimomab in hyperinflammatory response during severe sepsis: The RAMSES Study.
    Reinhart K; Menges T; Gardlund B; Harm Zwaveling J; Smithes M; Vincent JL; Tellado JM; Salgado-Remigio A; Zimlichman R; Withington S; Tschaikowsky K; Brase R; Damas P; Kupper H; Kempeni J; Eiselstein J; Kaul M
    Crit Care Med; 2001 Apr; 29(4):765-9. PubMed ID: 11373466
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab')2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels.
    Panacek EA; Marshall JC; Albertson TE; Johnson DH; Johnson S; MacArthur RD; Miller M; Barchuk WT; Fischkoff S; Kaul M; Teoh L; Van Meter L; Daum L; Lemeshow S; Hicklin G; Doig C;
    Crit Care Med; 2004 Nov; 32(11):2173-82. PubMed ID: 15640628
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A multicenter, open-label, prospective, randomized, dose-ranging pharmacokinetic study of the anti-TNF-alpha antibody afelimomab in patients with sepsis syndrome.
    Gallagher J; Fisher C; Sherman B; Munger M; Meyers B; Ellison T; Fischkoff S; Barchuk WT; Teoh L; Velagapudi R
    Intensive Care Med; 2001 Jul; 27(7):1169-78. PubMed ID: 11534565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging study.
    Reinhart K; Wiegand-Löhnert C; Grimminger F; Kaul M; Withington S; Treacher D; Eckart J; Willatts S; Bouza C; Krausch D; Stockenhuber F; Eiselstein J; Daum L; Kempeni J
    Crit Care Med; 1996 May; 24(5):733-42. PubMed ID: 8706447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: a randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients.
    Abraham E; Laterre PF; Garbino J; Pingleton S; Butler T; Dugernier T; Margolis B; Kudsk K; Zimmerli W; Anderson P; Reynaert M; Lew D; Lesslauer W; Passe S; Cooper P; Burdeska A; Modi M; Leighton A; Salgo M; Van der Auwera P;
    Crit Care Med; 2001 Mar; 29(3):503-10. PubMed ID: 11373411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group.
    Cohen J; Carlet J
    Crit Care Med; 1996 Sep; 24(9):1431-40. PubMed ID: 8797612
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p55 Tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. Ro 45-2081 Study Group.
    Abraham E; Glauser MP; Butler T; Garbino J; Gelmont D; Laterre PF; Kudsk K; Bruining HA; Otto C; Tobin E; Zwingelstein C; Lesslauer W; Leighton A
    JAMA; 1997 May; 277(19):1531-8. PubMed ID: 9153367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group.
    Abraham E; Wunderink R; Silverman H; Perl TM; Nasraway S; Levy H; Bone R; Wenzel RP; Balk R; Allred R
    JAMA; 1995 Mar 22-29; 273(12):934-41. PubMed ID: 7884952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of affinity-purified, anti-tumor necrosis factor-alpha, ovine fab for injection (CytoFab) in severe sepsis.
    Rice TW; Wheeler AP; Morris PE; Paz HL; Russell JA; Edens TR; Bernard GR
    Crit Care Med; 2006 Sep; 34(9):2271-81. PubMed ID: 16810105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endothelin in septic patients: effects on cardiovascular and renal function and its relationship to proinflammatory cytokines.
    Tschaikowsky K; Sägner S; Lehnert N; Kaul M; Ritter J
    Crit Care Med; 2000 Jun; 28(6):1854-60. PubMed ID: 10890632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of the immunomodulating agent, pentoxifylline, in the treatment of sepsis in prematurely delivered infants: a placebo-controlled, double-blind trial.
    Lauterbach R; Pawlik D; Kowalczyk D; Ksycínski W; Helwich E; Zembala M
    Crit Care Med; 1999 Apr; 27(4):807-14. PubMed ID: 10321674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of pentoxifylline in severe sepsis: results of a randomized, double-blind, placebo-controlled study.
    Staubach KH; Schröder J; Stüber F; Gehrke K; Traumann E; Zabel P
    Arch Surg; 1998 Jan; 133(1):94-100. PubMed ID: 9438767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomized, placebo-controlled, single-blind, dose escalation study.
    Abraham E; Reinhart K; Svoboda P; Seibert A; Olthoff D; Dal Nogare A; Postier R; Hempelmann G; Butler T; Martin E; Zwingelstein C; Percell S; Shu V; Leighton A; Creasey AA
    Crit Care Med; 2001 Nov; 29(11):2081-9. PubMed ID: 11700399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group.
    Opal SM; Fisher CJ; Dhainaut JF; Vincent JL; Brase R; Lowry SF; Sadoff JC; Slotman GJ; Levy H; Balk RA; Shelly MP; Pribble JP; LaBrecque JF; Lookabaugh J; Donovan H; Dubin H; Baughman R; Norman J; DeMaria E; Matzel K; Abraham E; Seneff M
    Crit Care Med; 1997 Jul; 25(7):1115-24. PubMed ID: 9233735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antithrombin III in patients with severe sepsis. A randomized, placebo-controlled, double-blind multicenter trial plus a meta-analysis on all randomized, placebo-controlled, double-blind trials with antithrombin III in severe sepsis.
    Eisele B; Lamy M; Thijs LG; Keinecke HO; Schuster HP; Matthias FR; Fourrier F; Heinrichs H; Delvos U
    Intensive Care Med; 1998 Jul; 24(7):663-72. PubMed ID: 9722035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluating the efficacy and safety of two doses of the polyclonal anti-tumor necrosis factor-α fragment antibody AZD9773 in adult patients with severe sepsis and/or septic shock: randomized, double-blind, placebo-controlled phase IIb study*.
    Bernard GR; Francois B; Mira JP; Vincent JL; Dellinger RP; Russell JA; Larosa SP; Laterre PF; Levy MM; Dankner W; Schmitt N; Lindemann J; Wittebole X
    Crit Care Med; 2014 Mar; 42(3):504-11. PubMed ID: 24335445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis.
    Rice TW; Wheeler AP; Bernard GR; Vincent JL; Angus DC; Aikawa N; Demeyer I; Sainati S; Amlot N; Cao C; Ii M; Matsuda H; Mouri K; Cohen J
    Crit Care Med; 2010 Aug; 38(8):1685-94. PubMed ID: 20562702
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase 2 trial of eritoran tetrasodium (E5564), a toll-like receptor 4 antagonist, in patients with severe sepsis.
    Tidswell M; Tillis W; Larosa SP; Lynn M; Wittek AE; Kao R; Wheeler J; Gogate J; Opal SM;
    Crit Care Med; 2010 Jan; 38(1):72-83. PubMed ID: 19661804
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Confirmatory platelet-activating factor receptor antagonist trial in patients with severe gram-negative bacterial sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. BN 52021 Sepsis Investigator Group.
    Dhainaut JF; Tenaillon A; Hemmer M; Damas P; Le Tulzo Y; Radermacher P; Schaller MD; Sollet JP; Wolff M; Holzapfel L; Zeni F; Vedrinne JM; de Vathaire F; Gourlay ML; Guinot P; Mira JP
    Crit Care Med; 1998 Dec; 26(12):1963-71. PubMed ID: 9875905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. E5 murine monoclonal antiendotoxin antibody in gram-negative sepsis: a randomized controlled trial. E5 Study Investigators.
    Angus DC; Birmingham MC; Balk RA; Scannon PJ; Collins D; Kruse JA; Graham DR; Dedhia HV; Homann S; MacIntyre N
    JAMA; 2000 Apr; 283(13):1723-30. PubMed ID: 10755499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.